Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).

Breast cancer resistance protein (BCRP) is an efflux transporter that plays an important role in drug disposition. The goal of this study was to investigate the interactions of azole antifungal agents, ketoconazole, itraconazole, fluconazole, and voriconazole, with BCRP. First, the effect of the azoles on BCRP efflux activity in BCRP-overexpressing HEK cells was determined by measuring intracellular pheophorbide A (PhA) fluorescence using flow cytometry. We found that keotoconazole and itraconazole significantly inhibited BCRP-mediated efflux of PhA at low microM concentrations. However, fluconazole only mildly inhibited and voriconazole did not inhibit BCRP efflux activity at concentrations up to 100 microM. The IC(50) value of ketoconazole for inhibition of BCRP-mediated PhA efflux was 15.3 +/- 6.5 microM. Ketoconazole and itraconazole also effectively reversed BCRP-mediated resistance of HEK cells to topotecan. When direct efflux of [(3)H]ketoconazole was measured in BCRP-overexpressing HEK cells, we found that [(3)H]ketoconazole was not transported by BCRP. Consistent with this finding, BCRP did not confer resistance to ketoconazole and itraconazole in HEK cells. Taken together, ketoconazole and itraconazole are BCRP inhibitors, but fluconazole and voriconazole are not. These results suggest that BCRP could play a significant role in the pharmacokinetic interactions of ketoconazole or itraconazole with BCRP substrate drugs.

[1]  Ron H J Mathijssen,et al.  Modulation of irinotecan metabolism by ketoconazole. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[3]  Qingcheng Mao,et al.  Role of the breast cancer resistance protein (ABCG2) in drug transport , 2005, The AAPS Journal.

[4]  S. Cisternino,et al.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. , 2004, Cancer research.

[5]  S. Ishijima,et al.  Characteristic biological effects of itraconazole on L929 fibroblasts and their cell membrane , 2000, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[7]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[8]  P. Houghton,et al.  Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.

[9]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[10]  M. Morris,et al.  EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES , 2005, Drug Metabolism and Disposition.

[11]  Jos H Beijnen,et al.  The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.

[12]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[13]  Suneet Shukla,et al.  The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.

[14]  P. Gubbins,et al.  Drug–drug interactions of antifungal agents and implications for patient care , 2005, Expert opinion on pharmacotherapy.

[15]  M. Morris,et al.  Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. , 2004, Molecular pharmacology.

[16]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[17]  Yi Zhang,et al.  BCRP Transports Dipyridamole and is Inhibited by Calcium Channel Blockers , 2005, Pharmaceutical Research.

[18]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[19]  Yang Dai,et al.  Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan , 2006, Cancer Chemotherapy and Pharmacology.

[20]  G. Kéri,et al.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.

[21]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[22]  I. Pastan,et al.  Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. , 1994, The Journal of urology.

[23]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[24]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. L. Nelson,et al.  ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION , 2004, Drug Metabolism and Disposition.

[26]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[27]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[29]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[30]  K. Cashman,et al.  The effect of probiotic bacteria on transepithelial calcium transport and calcium uptake in human intestinal-like Caco-2 cells. , 2006, Current issues in intestinal microbiology.

[31]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[32]  Yi Zhang,et al.  HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[33]  J. Unadkat,et al.  FUNCTIONAL ANALYSIS OF THE HUMAN VARIANTS OF BREAST CANCER RESISTANCE PROTEIN: I206L, N590Y, AND D620N , 2005, Drug Metabolism and Disposition.

[34]  D. Greenblatt,et al.  Effects of the Antifungal Agents on Oxidative Drug Metabolism , 2000, Clinical pharmacokinetics.

[35]  J. Schellens,et al.  Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles , 2004, Cancer Research.

[36]  E. Wang,et al.  Interaction of Common Azole Antifungals with P Glycoprotein , 2002, Antimicrobial Agents and Chemotherapy.

[37]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[38]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.